share_log

Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

再鼎醫藥(納斯達克:ZLAB)有債務但沒有盈利,你應該擔心嗎?
Simply Wall St ·  07/19 21:21

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. Importantly, Zai Lab Limited (NASDAQ:ZLAB) does carry debt. But the real question is whether this debt is making the company risky.

大衛·艾本說得好:“波動率並不是我們所關心的風險。我們關心的是避免永久性資本損失。”看起來理智的投資者知道,債務——通常是破產的因素——是評估公司風險的一個非常重要的因素。重要的是,再鼎醫藥(納斯達克:ZLAB)確實持有債務。但真正的問題是,這些債務是否使公司產生風險。

When Is Debt Dangerous?

債務何時有危險?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Of course, plenty of companies use debt to fund growth, without any negative consequences. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

債務能夠在公司遇到困難時提供幫助,如果公司無法通過新資本或自由現金流償還債務,則這些債務將最終導致股東損失慘重。然而,更常見(但仍然痛苦)的情況是,公司按低價發行新的股權資本,從而永久性地稀釋股東的權益。當然,有很多公司使用債務來資助公司的成長,而沒有任何負面的後果。因此,在考慮公司使用多少債務時,首先要看其現金和債務合起來。

How Much Debt Does Zai Lab Carry?

再鼎醫藥承擔了多少債務?

The image below, which you can click on for greater detail, shows that at March 2024 Zai Lab had debt of US$48.3m, up from none in one year. But on the other hand it also has US$650.8m in cash, leading to a US$602.5m net cash position.

下面的圖片可以點擊以查看更多詳細信息。截至2024年3月,再鼎醫藥的債務總計爲4830萬美元,而一年前則沒有債務。另一方面,它還有65080萬美元的現金,因此淨現金爲60250萬美元。

big
NasdaqGM:ZLAB Debt to Equity History July 19th 2024
納斯達克:ZLAb資本結構債務股本比歷史數據2024年7月19日

How Strong Is Zai Lab's Balance Sheet?

再鼎醫藥的資產負債表如何?

According to the last reported balance sheet, Zai Lab had liabilities of US$192.1m due within 12 months, and liabilities of US$34.2m due beyond 12 months. Offsetting these obligations, it had cash of US$650.8m as well as receivables valued at US$75.8m due within 12 months. So it actually has US$500.3m more liquid assets than total liabilities.

根據最後披露的資產負債表,再鼎醫藥有19210萬美元的負債到期,超過12個月則爲3420萬美元。對沖這些義務,它有65080萬美元的現金以及7580萬美元的應收款項到期回收。所以它實際上比總負債多出50030萬美元的流動資產。

This surplus suggests that Zai Lab is using debt in a way that is appears to be both safe and conservative. Given it has easily adequate short term liquidity, we don't think it will have any issues with its lenders. Simply put, the fact that Zai Lab has more cash than debt is arguably a good indication that it can manage its debt safely. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine Zai Lab's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

這種盈餘表明再鼎醫藥的債務使用方式看起來既安全又保守。由於其短期流動性充足,我們認爲它不會在與貸款人的關係上遇到任何問題。簡而言之,再鼎醫藥的現金超過債務,這可以被認爲是它能夠安全地管理債務的一個好跡象。在分析債務水平時,資產負債表是開始的明顯位置。但最終決定再鼎醫藥能否維持健康的資產負債表的關鍵因素,是未來的盈利能力。所以,如果你專注於未來,你可以查看這份免費報告,其中顯示了分析師利潤預測。

Over 12 months, Zai Lab reported revenue of US$291m, which is a gain of 26%, although it did not report any earnings before interest and tax. With any luck the company will be able to grow its way to profitability.

在過去的12個月中,再鼎醫藥報告了2.91億美元的營業收入,增長了26%,雖然它沒有報告任何利潤。希望公司能夠實現盈利。

So How Risky Is Zai Lab?

那麼再鼎醫藥的風險如何?

Statistically speaking companies that lose money are riskier than those that make money. And the fact is that over the last twelve months Zai Lab lost money at the earnings before interest and tax (EBIT) line. Indeed, in that time it burnt through US$223m of cash and made a loss of US$339m. While this does make the company a bit risky, it's important to remember it has net cash of US$602.5m. That kitty means the company can keep spending for growth for at least two years, at current rates. With very solid revenue growth in the last year, Zai Lab may be on a path to profitability. By investing before those profits, shareholders take on more risk in the hope of bigger rewards. There's no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet - far from it. For example, we've discovered 1 warning sign for Zai Lab that you should be aware of before investing here.

統計學上,虧損的公司比盈利的公司更具有風險性。事實上,在過去的12個月中,再鼎醫藥在利息和稅前利潤(EBIT)方面虧損。在那個時間裏,它燒去了2.23億美元的現金,虧損了3.39億美元。雖然這使得該公司有些冒險,但重要的是要記住,它擁有60250萬美元的淨現金。這筆錢意味着該公司至少可以以當前的速度持續用於成長兩年。在過去一年裏,再鼎醫藥的收入增長非常強勁,可能在走向盈利之路。通過在盈利之前進行投資,股東承擔了更多的風險,希望獲得更大的回報。毫無疑問,我們從資產負債表中了解最多的債務。然而,並非所有的投資風險都存在於資產負債表中,遠遠不止這些。例如,我們在此發現了1個再鼎醫藥的警示標誌,您在投資之前應該了解這些標誌。

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

說到底,有時更容易關注那些甚至不需要債務的公司。讀者可以免費查看零淨債務增長股票列表,立即獲得。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論